Premium
Surfactant protein D inhibits early airway response in Aspergillus fumigatus ‐sensitized mice
Author(s) -
Erpenbeck V. J.,
Ziegert M.,
CavaletBlanco D.,
Martin C.,
Baelder R.,
Glaab T.,
Braun A.,
Steinhilber W.,
Luettig B.,
Uhlig S.,
Hoymann H. G.,
Krug N.,
Hohlfeld J. M.
Publication year - 2006
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.2006.02524.x
Subject(s) - immunology , aspergillus fumigatus , allergen , medicine , surfactant protein d , eosinophilia , bronchoalveolar lavage , histamine , allergy , lung , asthma , bronchial hyperresponsiveness , ovalbumin , respiratory disease , pharmacology , antigen , immune system , innate immune system
Summary Background The surfactant protein SP‐D has been reported to reduce bronchial hyper‐responsiveness, blood eosinophilia, and T‐helper type 2 cytokines in models of allergic asthma. However, little is known about the functional effect of SP‐D on the early airway response upon allergen inhalation, which is an important feature of this disease. Objective We investigated whether SP‐D is able to reduce the immediate allergen‐induced mediator release and the early bronchial obstruction in addition to its effects on airway inflammation and bronchial hyperresponsiveness in an Aspergillus fumigatus mouse asthma model. Methods A. fumigatus ‐sensitized mice were treated with a recombinant fragment of human SP‐D or placebo. Lung functions were measured in orotracheally intubated, spontaneously breathing animals using body plethysmography. In addition, passively sensitized precision‐cut lung slices (PCLS) were used to determine the effect of SP‐D on allergen‐induced histamine release. Results SP‐D inhibited the allergen‐induced early airway response and reduced airway hyperresponsiveness compared with placebo. Eosinophilia in bronchoalveolar lavage and lung tissue was reduced after SP‐D treatment, possibly by reducing eotaxin levels in the lung. Furthermore, SP‐D treatment reduced the allergen‐induced histamine release from PCLS. Conclusions These data suggest that SP‐D not only reduces allergen‐induced eosinophilic inflammation and airway hyperresponsiveness but also provides protection against early airway obstruction by inhibition of early mediator release.